Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: Results from two phase 1 studies

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 728-734

  Kakuda, Thomas N ^a   Woodfall, Brian ^b   De Marez, Tine ^a   Peeters, Monika ^b   Vandermeulen, Kati ^b   Aharchi, Fatima ^b   Hoetelmans, Richard M W ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Anti infectives; Non nucleoside reverse transcriptase inhibitors; Pharmacokinetics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CLARITHROMYCIN; ETRAVIRINE; PYRIDAZINE DERIVATIVE; RIFABUTIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INTERACTION; HUMAN; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; PYRIDAZINES; RIFABUTIN; YOUNG ADULT;

EID: 84894027822     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt421     Document Type: Article

References (29)

1. Brooks JT, Kaplan JE, Holmes KK et al. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis 2009; 48: 609-11.
2. Buchacz K, Baker RK, Moorman AC et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22: 1345-54.
3. Kaplan JE, Benson C, Holmes KH et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 RR-4: 1-207.
4. Bonnet F, Lewden C, May T et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis 2005; 37: 482-7.
5. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40: 609-16.
6. Smit C, Geskus R,Walker S et al. CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741-9.
7. Benson CA,Williams PL, Cohn DLet al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebocontrolled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181: 1289-97.
8. Corti M, Palmero D. Mycobacterium avium complex infection in HIV/AIDS patients. Expert Rev Anti Infect Ther 2008; 6: 351-63.
9. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995; 28: 115-25.
10. Wallace RJ Jr, Brown BA, Griffith DE et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995; 171: 747-50.
11. Jordan MK, Polis MA, Kelly G et al. Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetyl rifabutin pharmacokinetics. Antimicrob Agents Chemother 2000; 44: 2170-2.
12. SousaM,PozniakA,BoffitoM.Pharmacokineticsandpharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008; 62: 872-8.
13. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-98.
14. Cohen Y, Perronne C, Truffot-Pernot C et al. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother 1992; 36: 2104-7.
15. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50: 25-39.
16. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 2010; 15: 817-29.
17. Kakuda TN, Schöller-Gyüre M, Workman C et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther 2008; 13: 655-61.
18. Schöller-Gyüre M, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789-96.
19. Sekar V, Lavreys L, Van de Casteele T et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54: 4440-5.
20. Sekar VJ, Spinosa-Guzman S, De Paepe E et al. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers. J Clin Pharmacol 2008; 48: 60-5.
21. Schöller-Gyüre M, Kakuda TN, Witek J et al. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers. J Clin Pharmacol 2013; 53: 202-10.
22. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
23. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
24. Katlama C, Haubrich R, Lalezari J et al. Efficacyand safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
25. Kakuda TN, Wade JR, Snoeck E et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther 2010; 88: 695-703.
26. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 Suppl 1: S3-13.
27. Weiner M, Benator D, Burman Wet al. Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-91.
28. Katlama C, Clotet B, MillsA et al. Efficacyand safety of etravirine atweek 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15: 1045-52.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. February 2013; 1-239. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf (15 October 2013, date last accessed).